This inventor holds 1 USPTO granted patent. Top assignee: University of Strathclyde. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Cherry Lindsey Wainwright: Innovator in Vascular Medicine
Introduction
Cherry Lindsey Wainwright is a notable inventor based in Glasgow, GB. He has made significant contributions to the field of vascular medicine, particularly in the prevention of restenosis. His innovative approach focuses on the local administration of farnesyl transferase inhibitors, which has the potential to revolutionize treatment methods.
Latest Patents
Wainwright holds a patent titled "Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis." This invention addresses the critical issue of restenosis following surgical procedures by allowing effective use of low dosages with minimal side effects. His work in this area is groundbreaking and has implications for improving patient outcomes.
Career Highlights
Wainwright is affiliated with the University of Strathclyde, where he continues to engage in research and development in the medical field. His dedication to innovation in vascular treatments has positioned him as a key figure in his area of expertise.
Collaborations
Wainwright has collaborated with esteemed colleagues such as Susan Pyne and Lorraine Work. Their combined efforts contribute to advancing research and developing effective medical solutions.
Conclusion
Cherry Lindsey Wainwright's contributions to vascular medicine through his innovative patent demonstrate his commitment to improving healthcare. His work not only addresses significant medical challenges but also paves the way for future advancements in the field.